26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 28 / Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04799288 (ClinicalTrials.gov) | September 24, 2021 | 13/3/2021 | Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis | Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis | HAM/TSP | Drug: Teriflunomide | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1/Phase 2 | United States |